Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study

[21] Smith MR(2021)Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer Can Urol Assoc J. 15 E281-9

[22] Hu JR(2021)NCCN guidelines insights: prostate cancer, version 1.2021 J Natl Compr Canc Netw 19 134-49

[23] Duncan MS(2016)What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Transl Androl Urol 5 235-31

[24] Morgans AK(2022)Trends in androgen deprivation use in men with intermediate-risk prostate cancer who underwent radiation therapy Adv Radiat Oncol 7 100904-8

[25] Brown JD(2020)Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study J Urol 203 1109-undefined

[26] Meijers WC(2015)The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada J Oncol 2015 820403-undefined

[27] Freiberg MS(2021)Assessment and management of cardiovascular risk factors among US veterans with prostate cancer JAMA Netw Open 4 e210070-undefined

[28] Roth GA(2022)2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 43 4229-undefined

[29] Mensah GA(2020)Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: a population-based patient-reported outcome study Psychooncology 29 886-undefined

[30] Johnson CO(2022)Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: a population-based competing-risk analysis Prostate. 82 1477-undefined

[21] Smith MR(2021)Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer Can Urol Assoc J. 15 E281-9

[22] Hu JR(2021)NCCN guidelines insights: prostate cancer, version 1.2021 J Natl Compr Canc Netw 19 134-49

[23] Duncan MS(2016)What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Transl Androl Urol 5 235-31

[24] Morgans AK(2022)Trends in androgen deprivation use in men with intermediate-risk prostate cancer who underwent radiation therapy Adv Radiat Oncol 7 100904-8

[25] Brown JD(2020)Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study J Urol 203 1109-undefined

[26] Meijers WC(2015)The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada J Oncol 2015 820403-undefined

[27] Freiberg MS(2021)Assessment and management of cardiovascular risk factors among US veterans with prostate cancer JAMA Netw Open 4 e210070-undefined

[28] Roth GA(2022)2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 43 4229-undefined

[29] Mensah GA(2020)Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: a population-based patient-reported outcome study Psychooncology 29 886-undefined

[30] Johnson CO(2022)Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: a population-based competing-risk analysis Prostate. 82 1477-undefined